Skip Navigation LinksHome > February 2011 - Volume 111 - Issue 2 > New Drug Minimizes Risk of Blood Clots in Atrial Fibrillatio...
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000394286.02212.73
Drug Watch

New Drug Minimizes Risk of Blood Clots in Atrial Fibrillation

Aschenbrenner, Diane S. MS, APRN-BC

Collapse Box

Abstract

* Dabigatran etexilate (Pradaxa) has been approved to lower the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation.

* In clinical trials, patients taking dabigatran had fewer ischemic and hemorrhagic strokes than patients taking warfarin.

* As with other anticoagulants, dabigatran may cause serious, even fatal, bleeding.

© 2011 Lippincott Williams & Wilkins, Inc.

Login